Dear Members and Friends of ACS,

Cannabis and cannabinoid medicine continues to evolve and the discussions at the state, national, and international levels continue to prioritize issues that conflict with patient care. The outcome of these discussions will shape patient treatment and our field for years to come.  I am proud that the Association of Cannabinoid Specialists (ACS) is on the forefront of this debate, advocating for our members and the patients we serve.

We strive to present members with meaningful education and tools to help them practice quality medicine.  See all of ACS’s member benefits here.

In addition, early career professionals can take advantage of ACS’s mentorship opportunities to connect with senior members to enhance their careers. More seasoned cannabis clinicians are encouraged participate in one of our committees or working groups. 

If you are a current member, I hope you will enjoy these expanded benefits.  If you are considering joining ACS, I hope that you will agree that ACS offers a tremendous value for all those committed to furthering both the art and science of cannabis medicine.  Student membership is free and recent graduates are offered a discounted rate!  Email [email protected] to learn more.

As always, I welcome your thoughts on additional ways ACS can support your practice and improve the care of the patients we treat.

Yours Truly,

Jordan Tishler, MD

President of the Association of Cannabinoid Specialists




The Association of Cannabinoid Specialists ensures the highest standards in the practice of cannabis medicine, safeguards patient care with clinical best practices, and interfaces with other stakeholders in the cannabis community.

We believe that patients are uniquely vulnerable and have very different needs than recreational users.

We provide evidence and experience-based education for patients, cannabis clinicians, referring clinicians, and lawmakers to help them understand cannabis medicine and make informed decisions.

We are an advocacy organization striving to provide guidance on best practices in the laws and regulations at the federal, state, and international levels.





Patients are a vulnerable group who deserve the highest standard of medical care and products.


Recreational use is not the same as medical use.  These groups have different goals and needs and must be addressed separately.


Prohibition of cannabis is a major public health hazard that has failed to decrease drug use and has led to unsupportable consequences.


Cannabis is medicine. It should be regulated like other medications and be available by prescription including in botanical form.


Cannabis products should not make unsubstantiated medical claims.  Products should be required to meet strict standards of safety, bioavailability, and efficacy.


Dispensaries should operate like pharmacies.  They should provide products that are safe and effective.  They should not provide medical advice to patients.  They should not contradict patients’ clinicians’ orders.






Our members provide the utmost in care for their patients. All members and their practices agree to abide by the following pledge:


All patients will be treated with a level of care consistent with highest medical ethics and standard of care equal to, or exceeding, any other medical specialty.


Records detailing prior and current treatment of illnesses relevant to cannabis treatment will be required of all patients, reviewed by clinicians, and properly filed in the medical record.


The purpose of a medical cannabis practice is to provide care for patients. Certification is only a tool to be used in that pursuit, and should be de-emphasized in favor of a holistic view of the patient and their needs.


Medications and allergies will be documented and reviewed at each visit (medication reconciliation). Medication reviews will be documented as well.


Cannabis patients require guidance by knowledgeable, caring specialists. Patients may have concerns and questions that are best not left to laypeople or non-cannabis specialists to address. Patients will receive ongoing care as at least every 6 months, more often, and for a length of visit, as is medically indicated, commensurate with other specialty care for similar illnesses. We advocate for 60 minute initial consultations, and 30 minute subsequent visits.



Women of childbearing age will receive additional counseling on risks of using medical cannabis during pregnancy and breastfeeding.

  Blue_bullet.png All patients will be reminded of the risks associated with driving or doing other generally hazardous activities while intoxicated.

Cannabis science and practice is changing rapidly. Specialists commit to keeping pace with these changes through reading of the literature or other continuing medical education of at least 20 hours per year.


Records of clinical encounters will be communicated to a patient’s primary care provider or other such provider as the patient chooses, unless the patient actively chooses not to allow communication.


Telemedicine visits are felt to be an inferior choice to in-person visits. They should be used only when circumstances make in-person visits impractical, perilous, or an undue hardship. Telemedicine should never be used in contravention of local law or regulation. At least annual in-person visits are strongly encouraged.


The same high level of care and ethics will be applied to all patients regardless of race, gender, age, sexual orientation, sexual identification, or economic background.


All encounters with patients will be properly documented in the EHR.


Neither the practice or any practitioner shall enter into any business arrangement that might cause an ethical conflict with patients’ best interests. Conflicts of interest, or apparent conflicts of interest, will be disclosed to patients, governing bodies, and the ACS.



The Association of Cannabinoid Specialists has multiple working departments that envision, plan, and implement the outreach and advocacy of the association. Below are the mission statements of each committee.

Student_books.png Donation_pig.png

The Education Department produces educational events, courses, and materials for both cannabinoid specialists and referring clinicians.


The Development Department seeks to increase membership by ensuring the benefits and relevance of Association activities to member needs.  It seeks donations from individuals and corporations to support ACS activities in a blind, non-quid-pro-quo manner.

Policy_gavel.png Flags_international.png

The Policy Department provides evidence, testimony, and guidance to governmental and non-governmental groups to help implement legal and regulatory systems that benefit cannabis patients and the clinicians who care for them.


The International Department seeks to connect cannabinoid specialists, medical professionals, advocates, and more from around the world, and to advocate for patients and caregivers globally.


The Student Department provides mentorship and guidance for those students looking to develop knowledge about cannabinoid medicine. 

This department also produces educational events designed specifically for students in different areas of cannabinoid medicine.